Related Experiment Video
Updated: Aug 17, 2025
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.0K
[Treatment-resistant depression. From classification to new therapies.]
Walter Paganin1, Sabrina Signorini2, Vincenzo Leccese3
1Dottorato di Neuroscienze, Università Tor Vergata, Roma.
Rivista Di Psichiatria
|December 12, 2022
Summary
Treatment-resistant depression (TRD) requires advanced therapies beyond standard antidepressants. Recent research highlights novel pharmacological and instrumental treatments, including esketamine and psilocybin, for improved patient outcomes.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Context:
- Major depressive disorder (MDD) poses significant challenges, particularly when patients do not respond to conventional antidepressant medications.
- Treatment resistance and pseudoresistance complicate diagnosis and therapeutic strategies for depression.
- The growing prevalence of TRD underscores the need for updated treatment guidelines and research.
Purpose:
- To review recent advancements in the recognition and treatment of treatment-resistant depression (TRD).
- To explore the concepts of depressive disorder, resistance, and pseudoresistance to pharmacotherapy.
- To examine current and emerging therapeutic interventions for TRD.
Summary:
- A comprehensive literature search identified key terms related to MDD, TRD, staging, and instrumental therapies.
- Emerging pharmacological agents like esketamine and psilocybin show promise for TRD.
- Instrumental therapies, including vagus nerve stimulation, deep brain stimulation, and various forms of neuromodulation, are increasingly utilized.
Impact:
- TRD presents a substantial public health issue, marked by high relapse rates, hospitalizations, and mortality.
- Effective management of TRD necessitates dedicated research protocols and clear diagnostic criteria.
- Future research must evaluate the benefits, risks, and costs of novel TRD therapies to optimize patient care and quality of life.
More Related Videos
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.7K
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
145
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
301
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
301
01:25Antidepressant Drugs: Overview
679
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
679
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
511
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
511
01:30Electroconvulsive Therapy
112
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
112
01:28Drug Therapy
83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
83
01:24Treatment Strategies for Psychological Disorders
249
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
249